C. Sima

发表

A Prospective Study of Tumor Suppressor Gene Methylation as a Prognostic Biomarker in Surgically Resected Stage I to IIIA Non–Small-Cell Lung Cancers

A. Drilon, H. Sugita, C. Sima, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens

C. Sima, W. Travis, N. Rekhtman, 2011, Modern Pathology.

Driver mutations determine survival in smokers and never‐smokers with stage IIIB/IV lung adenocarcinomas

M. Ladanyi, C. Sima, M. Kris, 2012, Cancer.

Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers

William Pao, Marc Ladanyi, Vincent A. Miller, 2013, Clinical Cancer Research.

Long-term Survival Based on the Surgical Approach to Lobectomy For Clinical Stage I Nonsmall Cell Lung Cancer: Comparison of Robotic, Video-assisted Thoracic Surgery, and Thoracotomy Lobectomy

Kaitlin M. Woo, David R. Jones, C. Sima, 2017, Annals of surgery.

A grading system combining architectural features and mitotic count predicts recurrence in stage I lung adenocarcinoma

Prasad S Adusumilli, Akihiko Yoshizawa, Gregory J Riely, 2012, Modern Pathology.

Optimal Cutpoint Estimation With Censored Data

Mithat Gönen, C. Sima, M. Gönen, 2013 .

A Grading System of Lung Adenocarcinomas Based on Histologic Pattern is Predictive of Disease Recurrence in Stage I Tumors

Akihiko Yoshizawa, C. Sima, V. Rusch, 2010, The American journal of surgical pathology.

Distinct profile of driver mutations and clinical features in immunomarker-defined subsets of pulmonary large-cell carcinoma.

M. Ladanyi, C. Sima, M. Kris, 2013, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

Impact of micropapillary histologic subtype in selecting limited resection vs lobectomy for lung adenocarcinoma of 2cm or smaller.

Prasad S Adusumilli, C. Sima, V. Rusch, 2013, Journal of the National Cancer Institute.

The cribriform pattern identifies a subset of acinar predominant tumors with poor prognosis in patients with stage I lung adenocarcinoma: a conceptual proposal to classify cribriform predominant tumors as a distinct histologic subtype

Prasad S Adusumilli, Yi-Chen Yeh, C. Sima, 2014, Modern Pathology.

Prognostic Significance of Adenocarcinoma In Situ, Minimally Invasive Adenocarcinoma, and Nonmucinous Lepidic Predominant Invasive Adenocarcinoma of the Lung in Patients With Stage I Disease

Akihiko Yoshizawa, William D. Travis, C. Sima, 2014, The American journal of surgical pathology.

Solid Predominant Histologic Subtype in Resected Stage I Lung Adenocarcinoma Is an Independent Predictor of Early, Extrathoracic, Multisite Recurrence and of Poor Postrecurrence Survival.

David R Jones, Prasad S Adusumilli, David R. Jones, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Classification of thymic epithelial neoplasms is still a challenge to thoracic pathologists: a reproducibility study using digital microscopy.

C. Sima, A. Saqi, P. Illei, 2014, Archives of pathology & laboratory medicine.

Estimating the Effect of a Time-Dependent Treatment by Levels of an Internal Time-Dependent Covariate: Application to the Contrast Between Liver Wait-List and Posttransplant Mortality

Robert M. Merion, Robert A. Wolfe, Douglas E. Schaubel, 2009 .

Palliation and Pleurodesis in Malignant Pleural Effusion: The Role for Tunneled Pleural Catheters

C. Sima, V. Rusch, S. Solomon, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Prevalence and Safety of Off-Label Use of Chemotherapeutic Agents in Older Patients With Breast Cancer: Estimates From SEER-Medicare Data.

C. Sima, K. Panageas, A. Eaton, 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: A comprehensive analysis reveals prognostic immune markers

David R. Jones, C. Sima, W. Travis, 2015, Oncoimmunology.

Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation

William Pao, Marc Ladanyi, Geoffrey R. Oxnard, 2010, Clinical Cancer Research.

Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinoma.

M. Ladanyi, C. Sima, M. Kris, 2010 .

An In Vivo Platform for Tumor Biomarker Assessment

C. Sima, V. Rusch, M. Sadelain, 2011, PloS one.

Pack years of cigarette smoking as a predictor of survival in 2,013 patients with stage IIIb/IV non-small cell lung cancer (NSCLC)

C. Sima, M. Kris, R. Shen, 2008 .

Minimally invasive (robotic assisted thoracic surgery and video-assisted thoracic surgery) lobectomy for the treatment of locally advanced non-small cell lung cancer.

C. Sima, K. Woo, Bernard J Park, 2016, Journal of thoracic disease.

Harnessing technology to improve clinical trials: study of real-time informatics to collect data, toxicities, image response assessments, and patient-reported outcomes in a phase II clinical trial.

A. Lash, L. Schwartz, Binsheng Zhao, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A prospective study of total plasma cell-free DNA as a predictive biomarker for response to systemic therapy in patients with advanced non-small-cell lung cancers.

A. Drilon, H. Sugita, C. Sima, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Neoadjuvant and adjuvant chemotherapy in resected pulmonary large cell neuroendocrine carcinomas: a single institution experience.

C. Sima, V. Rusch, G. Sica, 2011, The Annals of thoracic surgery.

Trial of a 5-day dosing regimen of temozolomide in patients with relapsed small cell lung cancers with assessment of methylguanine-DNA methyltransferase.

A. Drilon, C. Sima, M. Zauderer, 2014, Lung cancer.

A phase 1 study of everolimus plus docetaxel plus cisplatin as induction chemotherapy for patients with locally and/or regionally advanced head and neck cancer

C. Sima, A. Heguy, N. Katabi, 2013, Cancer.

Phase II Trial of Temozolomide in Patients with Relapsed Sensitive or Refractory Small Cell Lung Cancer, with Assessment of Methylguanine-DNA Methyltransferase as a Potential Biomarker

C. Sima, M. Kris, C. Azzoli, 2012, Clinical Cancer Research.

A phase I study of temsirolimus plus carboplatin plus paclitaxel for patients with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC)

C. Sima, N. Katabi, A. Ho, 2012, Cancer Chemotherapy and Pharmacology.

The effect of primary cytoreduction on outcomes of patients with FIGO stage IIIC ovarian cancer stratified by the initial tumor burden in the upper abdomen cephalad to the greater omentum.

C. Sima, R. Barakat, D. Chi, 2010, Gynecologic oncology.

Variability of lung tumor measurements on repeat computed tomography scans taken within 15 minutes.

L. Schwartz, Binsheng Zhao, C. Sima, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tissue and Serum Mesothelin Are Potential Markers of Neoplastic Progression in Barrett's Associated Esophageal Adenocarcinoma

C. Sima, V. Rusch, Laura H. Tang, 2012, Cancer Epidemiology, Biomarkers & Prevention.

Phase II study of docetaxel and vinorelbine as adjuvant chemotherapy for resected non-small cell lung cancers

C. Sima, M. Kris, V. Rusch, 2013, Cancer Chemotherapy and Pharmacology.

Pack‐years of cigarette smoking as a prognostic factor in patients with stage IIIB/IV nonsmall cell lung cancer

C. Sima, M. Kris, R. Shen, 2010, Cancer.

Differences in the survival of patients with recurrent versus de novo metastatic KRAS‐mutant and EGFR‐mutant lung adenocarcinomas

C. Sima, M. Kris, Gregory Riely, 2015, Cancer.

Thirty-day mortality underestimates the risk of early death after major resections for thoracic malignancies.

David R. Jones, C. Sima, V. Rusch, 2014, The Annals of thoracic surgery.

Coffee and tea consumption and endometrial cancer risk in a population-based study in New Jersey

C. Sima, A. Zauber, S. Olson, 2010, Cancer Causes & Control.

Serum Biomarkers Associated with Clinical Outcomes Fail to Predict Brain Metastases in Patients with Stage IV Non-Small Cell Lung Cancers

C. Sima, M. Zauderer, M. Kris, 2016, PloS one.

Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations.

M. Ladanyi, Michael Fara, C. Sima, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Feasibility and clinical impact of sharing patient-reported symptom toxicities and performance status with clinical investigators during a phase 2 cancer treatment trial

C. Sima, M. Kris, E. Basch, 2016, Clinical trials.

Management and outcomes of postpancreatectomy fistula, leak, and abscess: results of 908 patients resected at a single institution between 2000 and 2005.

C. Sima, K. Brown, A. Covey, 2008, Journal of the American College of Surgeons.

Cancer screening among patients with advanced cancer.

C. Sima, D. Schrag, K. Panageas, 2010, JAMA.

Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma.

C. Sima, M. Zauderer, M. Ginsberg, 2014, Lung cancer.

Clinical Characteristics and Outcomes for Patients With Thymic Carcinoma: Evaluation of Masaoka Staging

C. Sima, Gregory Riely, A. Moreira, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Sun Exposure, Vitamin D Receptor Genetic Variants, and Risk of Breast Cancer in the Agricultural Health Study

C. Sima, J. Satagopan, I. Orlow, 2013, Environmental health perspectives.

Vitamin D receptor gene haplotypes and polymorphisms and risk of breast cancer: a nested case-control study Biomarkers

C. Sima, J. Satagopan, I. Orlow, 2013 .

Vitamin D Receptor Gene Haplotypes and Polymorphisms and Risk of Breast Cancer: A Nested Case–Control Study

C. Sima, J. Satagopan, I. Orlow, 2012, Cancer Epidemiology, Biomarkers & Prevention.

Phase II study of cabozantinib for patients with advanced RET-rearranged lung cancers.

M. Ladanyi, A. Drilon, C. Sima, 2015 .

A phase 2 study of weekly albumin-bound paclitaxel (Abraxane®) given as a two-hour infusion

C. Sima, M. Kris, C. Azzoli, 2011, Cancer Chemotherapy and Pharmacology.

Cure models for the analysis of time‐to‐event data in cancer studies

C. Sima, M. Brennan, K. Panageas, 2013, Journal of surgical oncology.

Attaining Proficiency in Robotic-Assisted Minimally Invasive Esophagectomy While Maximizing Safety during Procedure Development

David R. Jones, C. Sima, V. Rusch, 2016, Innovations.

A phase I study of twice weekly pulse dose and daily low dose erlotinib as initial treatment for patients (pts) with EGFR-mutant lung cancers.

C. Sima, C. Rudin, M. Kris, 2015 .

Comparison of the characteristics and clinical course of 677 patients with metastatic lung cancers with mutations in KRAS codons 12 and 13.

M. Ladanyi, C. Sima, M. Kris, 2013 .

Small cell lung cancer (SCLC) among patients who are never smokers.

M. Berger, C. Sima, M. Kris, 2013 .

A phase 1 study of crizotinib and ganetespib (STA-9090) in ALK positive lung cancers.

C. Sima, M. Kris, Gregory Riely, 2015 .

Liver and Intestine Transplantation in the United States, 1996–2005

C. Sima, R. Merion, J. Lake, 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Pleomorphic Epithelioid Diffuse Malignant Pleural Mesothelioma: A Clinicopathological Review and Conceptual Proposal to Reclassify as Biphasic or Sarcomatoid Mesothelioma

C. Sima, V. Rusch, W. Travis, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Tumor Spread through Air Spaces is an Important Pattern of Invasion and Impacts the Frequency and Location of Recurrences after Limited Resection for Small Stage I Lung Adenocarcinomas

David R. Jones, C. Sima, W. Travis, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Tissue microarray evidence of association between p16 and phosphorylated eIF4E in tonsillar squamous cell carcinoma

C. Sima, J. Shah, N. Lee, 2011, Head & neck.

International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification predicts occult lymph node metastasis in clinically mediastinal node-negative lung adenocarcinoma.

David R Jones, Prasad S Adusumilli, David R. Jones, 2016, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

Using frozen section to identify histological patterns in stage I lung adenocarcinoma of ≤3 cm: accuracy and interobserver agreement

C. Sima, V. Rusch, A. Yoshizawa, 2015, Histopathology.

Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib

M. Ladanyi, C. Sima, M. Kris, 2015, Cancer.

Coexistence of PIK3CA and Other Oncogene Mutations in Lung Adenocarcinoma–Rationale for Comprehensive Mutation Profiling

M. Ladanyi, C. Sima, M. Kris, 2011, Molecular Cancer Therapeutics.

Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers.

M. Ladanyi, C. Sima, M. Kris, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Next-Generation Sequencing of Stage IV Squamous Cell Lung Cancers Reveals an Association of PI3K Aberrations and Evidence of Clonal Heterogeneity in Patients with Brain Metastases.

V. Seshan, M. Ladanyi, M. Berger, 2015, Cancer discovery.

Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma

William Pao, Hongbin Ji, Nicolas Girard, 2011, European Respiratory Journal.

Predicting the Risk of Perioperative Transfusion for Patients Undergoing Elective Hepatectomy

C. Sima, E. Elkin, M. Gönen, 2009, Annals of Surgery.

Airway basal cells of healthy smokers express an embryonic stem cell signature relevant to lung cancer

C. Sima, N. Hackett, J. Salit, 2013, Stem cells.

Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung Adenocarcinomas

M. Ladanyi, A. Drilon, C. Sima, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Mesothelin Overexpression Promotes Mesothelioma Cell Invasion and MMP-9 Secretion in an Orthotopic Mouse Model and in Epithelioid Pleural Mesothelioma Patients

C. Sima, V. Rusch, M. Sadelain, 2012, Clinical Cancer Research.

Thyroid transcription factor‐1 expression is an independent predictor of recurrence and correlates with the IASLC/ATS/ERS histologic classification in patients with stage I lung adenocarcinoma

C. Sima, V. Rusch, A. Yoshizawa, 2013, Cancer.

Next-Generation Sequencing of Stage IV Squamous Cell Lung Cancers Reveals an Association of PI 3 K Aberrations and Evidence of Clonal Heterogeneity in Patients with Brain Metastases

V. Seshan, M. Ladanyi, M. Berger, 2015 .

DRAFT FOR PUBLIC COMMENT Defining Clinically Meaningful Outcomes: ASCO Recommendations to Raise the Bar for Clinical Trials

L. Ellis, C. Sima, D. Sargent, 2013 .

Optimal Cutpoint Estimation with Censored Data Mithat Gonen

C. Sima, M. Gonen, 2017 .

A Prediction Model for Pathologic N2 Disease in Lung Cancer Patients with a Negative Mediastinum by Positron Emission Tomography

C. Sima, V. Rusch, N. Rizk, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma.

A. Zelenetz, C. Sima, J. Teruya-Feldstein, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pleural intensity-modulated radiotherapy for malignant pleural mesothelioma.

E. Yorke, K. Rosenzweig, C. Sima, 2012, International journal of radiation oncology, biology, physics.

Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas

M. Ladanyi, C. Sima, M. Kris, 2013, Cancer.

Predictive Biomarkers and Personalized Medicine Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer : Distinct Natural History of Patients with Tumors Harboring the T 790 M Mutation

M. Ladanyi, C. Sima, M. Kris, 2011 .

Distinct profile of driver mutations and clinical features in immunomarker-defined subsets of pulmonary large cell carcinoma

M. Ladanyi, C. Sima, M. Kris, 2012, Modern Pathology.

Exploratory analysis of serum CA-125 response to surgery and the risk of relapse in patients with FIGO stage IIIC ovarian cancer.

C. Sima, D. Levine, R. Barakat, 2009, Gynecologic oncology.

The Survival Benefit of Deceased Donor Liver Transplantation as a Function of Candidate Disease Severity and Donor Quality

C. Sima, R. Merion, D. Schaubel, 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Local Therapy with Continued EGFR Tyrosine Kinase Inhibitor Therapy as a Treatment Strategy in EGFR-Mutant Advanced Lung Cancers That Have Developed Acquired Resistance to EGFR Tyrosine Kinase Inhibitors

C. Sima, M. Kris, C. Azzoli, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Comprehensive Pathological Analyses in Lung Squamous Cell Carcinoma: Single Cell Invasion, Nuclear Diameter, and Tumor Budding Are Independent Prognostic Factors for Worse Outcomes

C. Sima, V. Rusch, W. Travis, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A nuclear grading system is a strong predictor of survival in epitheloid diffuse malignant pleural mesothelioma

C. Sima, V. Rusch, W. Travis, 2012, Modern Pathology.

Defining the immunologic phenotype of thymic epithelial tumors.

C. Sima, J. Wolchok, Gregory Riely, 2015 .

Large Cell Neuroendocrine Carcinoma of the Lung: Clinico-Pathologic Features, Treatment, and Outcomes.

C. Sima, C. Rudin, M. Kris, 2016, Clinical lung cancer.

Clinical Characteristics and Course of 63 Patients with BRAF Mutant Lung Cancers

M. Ladanyi, C. Sima, C. Rudin, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes.

L. Ellis, C. Sima, D. Sargent, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Distinct Clinical Course of EGFR-Mutant Resected Lung Cancers: Results of Testing of 1118 Surgical Specimens and Effects of Adjuvant Gefitinib and Erlotinib

M. Ladanyi, C. Sima, M. Kris, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Clinical Characteristics of Patients with Malignant Pleural Mesothelioma Harboring Somatic BAP1 Mutations

M. Ladanyi, C. Sima, M. Zauderer, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Maintained Sensitivity to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer Recurring after Adjuvant Erlotinib or Gefitinib

M. Ladanyi, C. Sima, M. Kris, 2011, Clinical Cancer Research.

High SUVmax on FDG-PET Indicates Pleomorphic Subtype in Epithelioid Malignant Pleural Mesothelioma: Supportive Evidence to Reclassify Pleomorphic as Nonepithelioid Histology

C. Sima, V. Rusch, W. Travis, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Prognostic Impact of KRAS Mutation Subtypes in 677 Patients with Metastatic Lung Adenocarcinomas

M. Ladanyi, C. Sima, M. Kris, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Chronic inflammation in tumor stroma is an independent predictor of prolonged survival in epithelioid malignant pleural mesothelioma patients

C. Sima, V. Rusch, W. Travis, 2011, Cancer Immunology, Immunotherapy.

Frequency of EGFR and KRAS Mutations in Lung Adenocarcinomas in African Americans

M. Ladanyi, C. Sima, M. Kris, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Risk of hemoptysis in patients with resected squamous cell and other high-risk lung cancers treated with adjuvant bevacizumab

C. Sima, M. Kris, V. Rusch, 2013, Cancer Chemotherapy and Pharmacology.

Tumor Budding Correlates With the Protumor Immune Microenvironment and Is an Independent Prognostic Factor for Recurrence of Stage I Lung Adenocarcinoma.

David R. Jones, C. Sima, W. Travis, 2015, Chest.

Phase 1 study of twice weekly pulse dose and daily low-dose erlotinib as initial treatment for patients with EGFR-mutant lung cancers.

C. Sima, C. Rudin, M. Kris, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Lungs Don’t Forget: Comparison of the KRAS and EGFR Mutation Profile and Survival of Collegiate Smokers and Never Smokers with Advanced Lung Cancers

M. Ladanyi, C. Sima, M. Kris, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas.

M. Ladanyi, C. Sima, M. Kris, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical impact of immune microenvironment in stage I lung adenocarcinoma: tumor interleukin-12 receptor β2 (IL-12Rβ2), IL-7R, and stromal FoxP3/CD3 ratio are independent predictors of recurrence.

C. Sima, V. Rusch, W. Travis, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Risk of Endometrial Cancer in Relation to Medical Conditions and Medication Use

C. Sima, A. Zauber, S. Olson, 2009, Cancer Epidemiology Biomarkers & Prevention.

Disease Flare after Tyrosine Kinase Inhibitor Discontinuation in Patients with EGFR-Mutant Lung Cancer and Acquired Resistance to Erlotinib or Gefitinib: Implications for Clinical Trial Design

C. Sima, M. Kris, Gregory Riely, 2011, Clinical Cancer Research.

Risk of cutaneous squamous cell carcinoma after treatment of basal cell carcinoma with vismodegib

M. Chren, S. Arron, C. Sima, 2017, Journal of the American Academy of Dermatology.

Nuclear estrogen receptor-α expression is an independent predictor of recurrence in male patients with pT1aN0 lung adenocarcinomas, and correlates with regulatory T-cell infiltration

David R. Jones, C. Sima, W. Travis, 2015, Oncotarget.

Tumoral CD10 expression correlates with high-grade histology and increases risk of recurrence in patients with stage I lung adenocarcinoma.

David R. Jones, C. Sima, W. Travis, 2015, Lung cancer.

Phase II Trial of Neoadjuvant Bevacizumab Plus Chemotherapy and Adjuvant Bevacizumab in Patients with Resectable Nonsquamous Non–Small-Cell Lung Cancers

C. Sima, M. Kris, V. Rusch, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Toxicity of initial chemotherapy in older patients with lung cancers.

C. Sima, M. Zauderer, M. Kris, 2013, Journal of geriatric oncology.

ReCAP: Detection of Potentially Avoidable Harm in Oncology From Patient Medical Records.

C. Sima, D. Classen, D. Pfister, 2016, Journal of oncology practice.

Resection of Primary Mediastinal Non-Seminomatous Germ Cell Tumors: A 28-Year Experience at Memorial Sloan-Kettering Cancer Center

C. Sima, V. Rusch, M. Bains, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Patterns of recurrence and second primary lung cancer in early-stage lung cancer survivors followed with routine computed tomography surveillance.

C. Sima, V. Rusch, P. Bach, 2013, The Journal of thoracic and cardiovascular surgery.

Esophageal Cancer Recurrence Patterns and Implications for Surveillance

C. Sima, V. Rusch, M. Bains, 2013, Journal of Thoracic Oncology.

Predicting pulmonary adenocarcinoma outcome based on a cytology grading system

C. Sima, W. Travis, K. Geisinger, 2012, Cancer cytopathology.

Phase II Trial of Dasatinib for Patients with Acquired Resistance to Treatment with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Erlotinib or Gefitinib

C. Sima, M. Kris, C. Azzoli, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma

David R. Jones, C. Sima, M. Kris, 2016, The American journal of surgical pathology.

Long-term central venous catheter use and risk of infection in older adults with cancer.

Coral L. Atoria, C. Sima, E. Elkin, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

C. Sima, M. Tonelli, B. Hemmelgarn, 2009, Journal of the American Society of Nephrology : JASN.

Adherence to the dietary guidelines for Americans and endometrial cancer risk

C. Sima, A. Zauber, S. Olson, 2010, Cancer Causes & Control.

C-reactive Protein and Risk of Colorectal Adenoma According to Celecoxib Treatment

P. Ridker, C. Sima, A. Zauber, 2011, Cancer Prevention Research.

Recurrence patterns after resection of soft tissue sarcomas of the chest wall.

C. Sima, V. Rusch, James Huang, 2013, The Annals of thoracic surgery.

Resection of Primary and Secondary Tumors of the Sternum: An Analysis of Prognostic Variables.

David R. Jones, C. Sima, V. Rusch, 2015, The Annals of thoracic surgery.

A prospective trial comparing pain and quality of life measures after anatomic lung resection using thoracoscopy or thoracotomy.

C. Sima, V. Rusch, M. Bains, 2014, The Annals of thoracic surgery.

Early Quality of Life Outcomes After Robotic-Assisted Minimally Invasive and Open Esophagectomy.

David R. Jones, C. Sima, V. Rusch, 2019, The Annals of thoracic surgery.

Physician-Driven Variation in Nonrecommended Services Among Older Adults Diagnosed With Cancer.

Coral L. Atoria, C. Sima, E. Elkin, 2016, JAMA internal medicine.

Mesothelin Overexpression Is a Marker of Tumor Aggressiveness and Is Associated with Reduced Recurrence-Free and Overall Survival in Early-Stage Lung Adenocarcinoma

C. Sima, V. Rusch, W. Travis, 2013, Clinical Cancer Research.

Associations Between Mutations and Histologic Patterns of Mucin in Lung Adenocarcinoma: Invasive Mucinous Pattern and Extracellular Mucin Are Associated With KRAS Mutation

Prasad S Adusumilli, Deborah Kuk, Yi-Chen Yeh, 2014, The American journal of surgical pathology.

Provider Differences in Use of Implanted Ports in Older Adults With Cancer

Coral L. Atoria, C. Sima, E. Elkin, 2015, Medical care.

Prognostic Impact of Immune Microenvironment in Lung Squamous Cell Carcinoma: Tumor-Infiltrating CD10+ Neutrophil/CD20+ Lymphocyte Ratio as an Independent Prognostic Factor

David R. Jones, C. Sima, W. Travis, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Re-weighting the model for end-stage liver disease score components.

C. Sima, A. Lok, R. Merion, 2008, Gastroenterology.

Urmila ChandranElisa V. BanderaMelony G. Williams-King •

C. Sima, S. Bayuga, 2010 .

Phytoestrogen consumption and endometrial cancer risk: a population-based case–control study in New Jersey

C. Sima, A. Zauber, S. Olson, 2009, Cancer Causes & Control.

Second primary lung cancers: smokers versus nonsmokers after resection of stage I lung adenocarcinoma.

David R. Jones, C. Sima, V. Rusch, 2014, The Annals of thoracic surgery.

Response to Erlotinib in Patients with EGFR Mutant Advanced Non–Small Cell Lung Cancers with a Squamous or Squamous-like Component

M. Ladanyi, C. Sima, M. Kris, 2012, Molecular Cancer Therapeutics.

Comparison of the KRAS/EGFR mutation profile and survival of “collegiate smokers” and never smokers with advanced lung cancers.

M. Ladanyi, A. Drilon, C. Sima, 2012 .

Differences in patterns of recurrence in early-stage versus locally advanced non-small cell lung cancer.

David R. Jones, C. Sima, V. Rusch, 2014, The Annals of thoracic surgery.

Serum biomarkers for assessing histology and outcomes in patients with metastatic lung cancer.

C. Sima, M. Kris, C. Azzoli, 2014, Cancer biomarkers : section A of Disease markers.

Variants in hormone biosynthesis genes and risk of endometrial cancer

C. Sima, A. Zauber, S. Olson, 2008, Cancer Causes & Control.

Long-term Survival Based on the Surgical Approach to Lobectomy For Clinical Stage I Nonsmall Cell Lung Cancer: Comparison of Robotic, Video-assisted Thoracic Surgery, and Thoracotomy Lobectomy.

David R. Jones, C. Sima, V. Rusch, 2016, Annals of Surgery.

1229PDSMOKING HISTORY AND RESPONSE TO NIVOLUMAB IN PATIENTS WITH ADVANCED NSCLCS.

C. Sima, S. Gettinger, M. Hellmann, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical Outcomes with Perioperative Chemotherapy in Sarcomatoid Carcinomas of the Lung

C. Sima, M. Kris, C. Azzoli, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Visceral pleural invasion does not affect recurrence or overall survival among patients with lung adenocarcinoma ≤ 2 cm: a proposal to reclassify T1 lung adenocarcinoma.

C. Sima, V. Rusch, W. Travis, 2013, Chest.

A phase II study of pralatrexate with vitamin B12 and folic acid supplementation for previously treated recurrent and/or metastatic head and neck squamous cell cancer

C. Sima, J. Lyo, A. Ho, 2014, Investigational New Drugs.

Preoperative Consolidation-to-Tumor Ratio and SUVmax Stratify the Risk of Recurrence in Patients Undergoing Limited Resection for Lung Adenocarcinoma ≤2 cm

C. Sima, V. Rusch, M. Dunphy, 2013, Annals of Surgical Oncology.

FDG-PET SUVmax Combined with IASLC/ATS/ERS Histologic Classification Improves the Prognostic Stratification of Patients with Stage I Lung Adenocarcinoma

C. Sima, V. Rusch, A. Yoshizawa, 2012, Annals of Surgical Oncology.

Use of high technology imaging for surveillance of early stage breast cancer

C. Sima, L. Liberman, D. Schrag, 2011, Breast Cancer Research and Treatment.

Local therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors.

A. Drilon, C. Sima, M. Kris, 2012 .

Tumoral CD10 Expression Correlates with Aggressive Histology and Prognosis in Patients with Malignant Pleural Mesothelioma

David R. Jones, C. Sima, W. Travis, 2015, Annals of Surgical Oncology.

The tumor immune microenvironment in octogenarians with stage I non-small cell lung cancer

David R. Jones, C. Sima, W. Travis, 2014, Oncoimmunology.

Pretreatment Dysphagia in Esophageal Cancer Patients May Eliminate the Need for Staging by Endoscopic Ultrasonography.

David R. Jones, C. Sima, V. Rusch, 2016, The Annals of thoracic surgery.

Clinical Characteristics and Course of 63 Patients with BRAF Mutant Lung Cancers

M. Ladanyi, C. Sima, C. Rudin, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers

M. Ladanyi, C. Sima, M. Kris, 2013, Clinical Cancer Research.

American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes.

L. Ellis, C. Sima, D. Sargent, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Frequency of EGFR and KRAS Mutations in Lung Adenocarcinomas in African Americans

M. Ladanyi, C. Sima, M. Kris, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Mesothelin Overexpression Is a Marker of Tumor Aggressiveness and Is Associated with Reduced Recurrence-Free and Overall Survival in Early-Stage Lung Adenocarcinoma

C. Sima, V. Rusch, W. Travis, 2013, Clinical Cancer Research.

1229PDSMOKING HISTORY AND RESPONSE TO NIVOLUMAB IN PATIENTS WITH ADVANCED NSCLCS.

C. Sima, N. Rizvi, M. Hellmann, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Tissue microarray evidence of association between p16 and phosphorylated eIF4E in tonsillar squamous cell carcinoma

C. Sima, J. Shah, N. Lee, 2011, Head & neck.

Differences in patterns of recurrence in early-stage versus locally advanced non-small cell lung cancer.

David R. Jones, C. Sima, V. Rusch, 2014, The Annals of thoracic surgery.

Coexistence of PIK3CA and Other Oncogene Mutations in Lung Adenocarcinoma–Rationale for Comprehensive Mutation Profiling

M. Ladanyi, C. Sima, M. Kris, 2011, Molecular Cancer Therapeutics.